Effects of folic acid and vitamin B complex on serum C-reactive protein and albumin levels in stable hemodialysis patients

References

• Bautista LE, Arenas IA, Penuela A, et al. Total plasma homo-cysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol 2002;55:882–7
   PubMed Web of Science ®Google Scholar
• Nurk E, Tell GS, Vollset SE, et al. Plasma total homocysteine and hospitalizations for cardiovascular disease: The Hordaland Homocysteine Study. Arch Intern Med 2002;162:1374–81
   PubMed Web of Science ®Google Scholar
• Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001;61:1549–57
   Google Scholar
• Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998;97:138–41
   PubMed Web of Science ®Google Scholar
• Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002;61:609–14
   PubMed Web of Science ®Google Scholar
• Suliman ME, Qureshi AR, Barany P, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000;57:1727–35
   PubMed Web of Science ®Google Scholar
• Wrone EM, Hornberger JM, Zehnder JL, et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420–6
   PubMed Web of Science ®Google Scholar
• Kalntar-Zadeh K, Block G, Humphreys MH, et al. A low, rather a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004;15:442–53
   Google Scholar
• Ducloux D, Klein A, Kazory A, et al. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int 2006;69:331–5
   PubMed Web of Science ®Google Scholar
• Suliman ME, Stenvinkel P, Qureshi AR, et al. The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant 2007;22:209–17
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F. Homocysteine and risk in end-stage renal disease: a matter of context. Kidney Int 2006;69:204–6
   PubMed Web of Science ®Google Scholar
• Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004;350:2673–81
   PubMed Web of Science ®Google Scholar
• Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578–88
   PubMed Web of Science ®Google Scholar
• Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567–77
   PubMed Web of Science ®Google Scholar
• Righetti M, Serbelloni P, Milani S, et al. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purify 2006;24:379–86
   PubMed Web of Science ®Google Scholar
• Prasad K. C-reactive protein-lowering agent. Cardiovasc Drug Rev 2006;24:33–50
   PubMed Web of Science ®Google Scholar
• Dierkes J, Wesphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 2005;5:124–39
   PubMedGoogle Scholar
• Kloppenburg WD, Stegeman CA, Hooyschuur M, et al. Assessing dialysis adequacy and dietary intake in the individual hemodialysis patient. Kidney Int 1999;55:1961–9
   PubMed Web of Science ®Google Scholar
• Burr T. Two sample hemodialysis urea kinetic modeling. Validation of the method. Nephron 1995;69:49–53
   PubMedGoogle Scholar
• Daugridas JT, Schneditz D. Overestimation of hemodialysis dose depends on dialysis efficiency by regional blood flow, but not by conventional 2-pool urea kinetic analysis. ASAIO J 1995;41:M719–24
   PubMedGoogle Scholar
• Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648–58
   PubMed Web of Science ®Google Scholar
• Yeun JY, Levine RA, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469–76
   PubMed Web of Science ®Google Scholar
• Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 2002;22:6–13
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Verbeke F, Schrijvers BF, et al. Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure? Kidney Int 2002;61:1199–209
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hankey GJ. Associations of homocysteine, C reactive protein and cardiovascular disease in patients with renal disease. Curr Opin Nephrol Hypertens 2001;10:377–83
   PubMed Web of Science ®Google Scholar
• Misra HP. Generation of superoxide free radical during the autoxidation of thiols. J Biol Chem 1974;249:2151–5
   PubMed Web of Science ®Google Scholar
• Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappa B-induced loss of Myo D messenger RNA: possible role in muscle decay and cachexia. Science 2000;289:2363–6
   PubMed Web of Science ®Google Scholar
• Kanani PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 1999;100:1161–8
   PubMed Web of Science ®Google Scholar
• Friedman AN, Bostom AG, Selhub J, et al. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001;12:2181–9
   PubMed Web of Science ®Google Scholar
• Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107–14
   PubMed Web of Science ®Google Scholar
• Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998;54:236–44
   PubMed Web of Science ®Google Scholar
• Cavaillon JM, Pngnet JL, Fitting C, Delons S. Serum interleukin-6 in long-term hemodialysis patients. Nephron 1992;60:307–13
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Heimburger O, Lindholm B, et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation, and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;61:953–60
   Google Scholar
• Kaysen GA, Chertow GM, Adhikarla R, et al. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001;60:333–40
   PubMed Web of Science ®Google Scholar
• Moshage HJ, Janssen JA, Franssen JH, et al. Study of the molecular mechanisms of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987;79:1635–41
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition-inflammation complex syndrome in dialysis patients: cause and consequences. Am J Kidney Dis 2003;42:864–81
   Google Scholar
• Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 1998;32 (Suppl 4):S118–25
   PubMedGoogle Scholar
• Vernaglione L, Cristofano C, Muscogiuri P, et al. Dose atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004;43:471–8
   PubMed Web of Science ®Google Scholar
• Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999;19:217–46
   PubMed Web of Science ®Google Scholar
• Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000;80:1107–213
   PubMed Web of Science ®Google Scholar